GMP Manufacturer API Atorvastatin Calcium CAS 134523-03-8

Superiority:

Introduction:
Atorvastatin calcium is a HMG CoA reductase inhibitor. It is white or almost white crystalline powder, insoluble in pH ≤ 4 aqueous solution, slightly soluble in water, pH 7.4 phosphate buffer, acetonitrile, slightly soluble in ethanol, easily soluble in methanol.


Function:
1.It mainly inhibits the synthesis of HMGCoA reductase, so as to inhibit the synthesis of cholesterol in vivo, and reduce the content of serum low density lipoprotein cholesterol and triglyceride.

2.Atorvastatin calcium can inhibit the synthesis of cholesterol, interfere with the production of lipoprotein, reduce the level of serum total cholesterol, effectively reduce the level of serum triglyceride, but also increase the level of serum high-density lipoprotein cholesterol.

3.It can reduce the plasma LDL-C level in some homozygous familial hypercholesterolemia patients, but this type of population has little response to other lipid-lowering drugs.

4.It is clinically used for primary hypercholesterolemia, mixed hyperlipidemia, hypertriglyceridemia, homozygous familial hypercholesterolemia and prevention and treatment of atherosclerosis.

It is white or off-white crystalline powder, insoluble in aqueous solution with pH≤4, slightly soluble in water, phosphate buffer with pH 7.4, acetonitrile, slightly soluble in ethanol, and easily soluble in methanol.

English name: Atorvastatin calcium

CAS number: 134523-03-8

Molecular formula: C66H68CaF2N4O10

Molecular weight: 1155.36

EINECS Number: 200-659-6

Atorvastatin calcium is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Mainly by inhibiting the synthesis of HMGCoA reductase, thereby inhibiting the synthesis of cholesterol in the body and reducing the content of serum low-density lipoprotein cholesterol and triglyceride. Because atorvastatin calcium inhibits the synthesis of cholesterol by cells, interferes with the production of lipoproteins, reduces the level of serum total cholesterol, can effectively reduce the level of serum triglyceride, and can also increase the level of serum high-density lipoprotein cholesterol. Lowers plasma LDL cholesterol levels in some patients with homozygous familial hypercholesterolemia, a population that rarely responds to other lipid-lowering drugs. Clinically used for primary hypercholesterolemia, mixed hyperlipidemia, hypertriglyceridemia, homozygous familial hypercholesterolemia and prevention and treatment of atherosclerosis. Statins are hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor class of hypolipidemic drugs developed in the late 1980s. Since the advent of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, etc. have been used in clinical, occupying an extremely important position in blood lipid-lowering drugs. Among them, atorvastatin calcium (Lipitor) has been the No. 1 best-selling drug in the world since 2000. Affected by the imminent expiration of patents, the global market sales in 2009 were US$12.3 billion, compared with US$13.288 billion in 2008. has declined. Nonetheless, as the only drug with annual sales exceeding 10 billion US dollars for many years, as the patent is about to expire, the optimization of its new synthesis process has once again attracted the attention of scientists.